Altimmune, Inc.NASDAQ: ALT

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

· Issued by Altimmune, Inc. via GlobeNewswire

GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:

Conference:Guggenheim SMID Cap Biotech Conference
Date/Time:Wednesday, February 5, 2025, at 9:30 a.m. EST

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450[email protected]

Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403[email protected]

Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657[email protected]

Primary Logo

Source: Altimmune, Inc

Altimmune, Inc. on 6ix

Story so far

Earlier from Altimmune

Later from Altimmune

All Altimmune news releases